Hsbc Holdings PLC Acquires New Holdings in Ingevity Corporation $NGVT

Key Points

• Hsbc Holdings PLC acquired 20,925 shares of Ingevity in the second quarter, valued at approximately $1.57 million. Institutional investors collectively own 91.59% of the company, including a newly reported $400.5 million BlackRock position.
• Ingevity reported quarterly EPS of $1.74, exceeding analyst expectations of $1.33, while revenue reached $314.1 million versus the $312.2 million consensus estimate. The company issued fiscal 2026 EPS guidance of $5.00–$5.45.
• Analysts maintain a generally neutral view, with two Buy ratings and three Holds; the average rating is Hold with an $80 price target. Meanwhile, company insiders sold 17,801 shares worth approximately $1.35 million over the past three months.

Hsbc Holdings PLC acquired a new position in shares of Ingevity Corporation (NYSE:NGVT - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 20,925 shares of the company's stock, valued at approximately $1,568,000. Hsbc Holdings PLC owned approximately 0.06% of Ingevity at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NGVT. BlackRock Inc. purchased a new stake in shares of Ingevity during the second quarter worth about $400,545,000. Millennium Management LLC raised its holdings in shares of Ingevity by 1.3% in the 3rd quarter. Millennium Management LLC now owns 1,189,524 shares of the company's stock worth $65,650,000 after purchasing an additional 15,562 shares during the period. Royce & Associates LP raised its holdings in shares of Ingevity by 7.7% in the 4th quarter. Royce & Associates LP now owns 1,111,158 shares of the company's stock worth $65,758,000 after purchasing an additional 79,059 shares during the period. Brown Advisory Inc. raised its holdings in Ingevity by 15.4% in the fourth quarter. Brown Advisory Inc. now owns 1,040,944 shares of the company's stock valued at $61,603,000 after buying an additional 138,859 shares during the period. Finally, Simcoe Capital Management LLC lifted its position in Ingevity by 9.4% during the fourth quarter. Simcoe Capital Management LLC now owns 1,020,945 shares of the company's stock valued at $60,420,000 after buying an additional 87,490 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company's stock.

Insiders Place Their Bets

In related news, SVP Ryan Fisher sold 2,709 shares of Ingevity stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $73.72, for a total transaction of $199,707.48. Following the sale, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. The trade was a 14.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Li sold 5,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the sale, the chief executive officer directly owned 120,636 shares of the company's stock, valued at $9,147,827.88. The trade was a 3.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,801 shares of company stock worth $1,347,481 over the last three months. Corporate insiders own 0.88% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NGVT shares. Wall Street Zen downgraded Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings upgraded shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Ingevity presently has an average rating of "Hold" and an average price target of $80.00.

Ingevity Price Performance

Shares of NYSE:NGVT opened at $69.64 on Friday. The firm's 50 day moving average is $72.63 and its two-hundred day moving average is $71.43. The firm has a market capitalization of $2.39 billion, a P/E ratio of 47.38 and a beta of 1.17. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. Ingevity Corporation has a 52 week low of $45.85 and a 52 week high of $79.29.

Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The business had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Analysts anticipate that Ingevity Corporation will post 5.4 earnings per share for the current year.

Ingevity Company Profile

Ingevity Corporation NYSE: NGVT is a specialty chemicals and materials company that develops products designed to improve performance, sustainability and resource efficiency across a range of industrial and consumer applications. Its businesses serve automotive, infrastructure, industrial, agricultural and other end markets.

The company's portfolio includes activated carbon products used in vehicle evaporative-emissions control systems, industrial air and water purification, and other filtration applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.